Full
Outline
This study systematically investigated the therapeutic mechanism of matrine derivative, (6aS, 10S, 11aR, 11bR, 11cS)-10-methylaminododecahydro-3a, 7a-diaza-benzo (de) anthracene-8-thione (MASM), in experimental autoimmune encephalomyelitis (EAE) through multi-dimensional analysis. The myelin oligodendrocyte glycoprotein MOG35-55/pertussis toxin-induced EAE mouse model was established, and neurological impairment was confirmed using Kono's 5-point scoring system, mice with scores between 0.5 and 3.5 were considered successful models. These mice were randomly divided into six groups: EAE control, MASM groups (1.5, 3 and 6 mg·kg-1), a positive control group (fingolimod, 1.0 mg·kg-1), and a normal control group. Drug administration was initiated on the day of grouping, once daily for 21 consecutive days. The Kono's score was used to evaluate the neurological function; HE staining and electron microscopy was used to observe the pathological changes of spinal cord; transforming growth factor-β1 and monocyte chemoattractant protein-1 content was detected by ELISA. The gene expression of H2T23 was detected by qRT-PCR, the binding interactions between MASM and human frizzled homolog (FZD5) was evaluated by molecular docking, and protein expression levels of glial fibrillary acidic protein (GFAP), complement 3 (C3), wingless type mouse mammary tumor virus integration site family member 5a (Wnt5a), FZD5, protein kinase Cα (PKCα), and the phosphorylation level of glycogen synthase kinase 3 (GSK3β) were detected by Western blot. MASM significantly improved neurological function, reduced spinal cord inflammation and demyelination, and downregulated astrocyte activation markers (GFAP, C3, H2T23) (P < 0.05, P < 0.01) and Wnt5a/FZD5 pathway components (Wnt5a, FZD5, PKCα, p-GSK3β) (P < 0.05, P < 0.01). MASM demonstrates strong binding capacity to FZD. These findings suggest that MASM alleviates EAE by inhibiting astrocyte polarization via the Wnt5a/FZD5 pathway. The animal study was approved by the Animal Ethics Committee of Fujian University of Traditional Chinese Medicine (approval number: FJTCMIACUC 2023319).
171
86
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
